Severe Persistent Asthma Clinical Trial
— PRESHOfficial title:
Prevalence of Hyperventilation Syndrome in Difficult Asthmatics Uncontrolled Despite a Daily Maximal Doses of Inhaled Treatment
Verified date | April 2018 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Most of asthmatics patients remain uncontrolled despite an inhaled steroids treatment. Chronic hyperventilation syndrome (also called Idiopathic Hyperventilation) occurs in 20 to 40% of asthmatic patients. The purpose of the study is to assess the prevalence of chronic hyperventilation syndrome in a specific population of difficult-to-treat asthmatics patients, those who receive daily high doses of inhaled steroids (≥ 1000 µg of fluticasone with an additional treatment by a long-acting beta 2-agonist (LABA) and who remain uncontrolled (Asthma control test (ACT) < 18). We plan to realize a systematic assessment of the diagnosis of chronic hyperventilation syndrome with the Nijmegen questionnaire, blood gases at rest, hyperventilation testing and Cardiopulmonary Exercise Testing(CPET). We also will collect demographic information as well as information about asthma history, asthma control and treatment.
Status | Completed |
Enrollment | 151 |
Est. completion date | October 18, 2016 |
Est. primary completion date | October 18, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - men and women, - aged more than 18, - non smokers for two years or longer, less than 10 pack/years smoking history, - physician-diagnosed asthma, - uncontrolled asthma with Asthma control test (ACT) < 18, - historical of FEV1 reversibility, - daily inhaled steroids treatment by at least 2000microg eq beclomethasone, - Forced expiratory volume in 1 second (FEV1) > 50% predicted value Exclusion Criteria: - other chronic pulmonary disease, - vocal cord dysfunction, - pregnancy, - Participation in another interventional research trial, - unable to provide consent, - asthma exacerbation within the last 4 weeks |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital | Le Kremlin-bicetre |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic of the hyperventilation syndrome | value of Nijmegen questionnaire, of blood gases at rest, of hyperventilation testing and of CPET | Up to 4 hours | |
Secondary | Assess the diagnosis value of the nijmegen questionnaire. | Up to 4 hours | ||
Secondary | Assess the diagnosis value of the blod gases at rest. | up to 4 hours | ||
Secondary | Assess the diagnosis value of the hyperventilation challenge. | Up to 4 hours | ||
Secondary | Assess the diagnosis value of the CPET. | Up to 4 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01197482 -
Inhaled Steroids and Control of Severe Asthma
|
||
Withdrawn |
NCT02952066 -
Expressions of TRPV1 in Airway of Asthmatics
|
N/A | |
Completed |
NCT02559791 -
Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
|
Phase 2/Phase 3 | |
Recruiting |
NCT03617718 -
Project 2 Airway Potential Hydrogen (pH) in Asthma
|
Phase 1/Phase 2 | |
Recruiting |
NCT01839591 -
Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa
|
N/A | |
Withdrawn |
NCT00954850 -
A National Program for Severe Asthma: The Canadian Severe Asthma Network
|
N/A | |
Withdrawn |
NCT01745809 -
Bronchoscopy Study for Severe Asthma
|
N/A | |
Completed |
NCT01748175 -
Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
|
||
Completed |
NCT02717689 -
A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma
|
N/A | |
Completed |
NCT01750411 -
Severe Asthma Research Program - Wake Forest University
|
||
Completed |
NCT02659618 -
Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma
|
||
Withdrawn |
NCT00689806 -
Evaluation of Lovastatin in Severe Persistent Asthma
|
Phase 1/Phase 2 |